Trials / Completed
CompletedNCT02516618
Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Fasinumab in Healthy Japanese and Caucasian Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to assess the safety and tolerability of a single dose of subcutaneous (SC) or intravenous (IV) administered fasinumab in healthy Japanese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fasinumab | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2015-08-06
- Last updated
- 2016-05-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02516618. Inclusion in this directory is not an endorsement.